Ser/Thr Kinase Inhibitor

Ser/Thr Kinase Inhibitors (30):

Cat. No.	Product Name	Effect	Purity

HY-138489

TRULI	Inhibitor	99.98%
TRULI (Lats-IN-1) is a potent and ATP-competitive inhibitor of Lats1 and Lats2 kinases. TRULI promotes Yap-dependent proliferation in postmitotic mammalian tissues.

HY-161111

KVS0001	Inhibitor	99.14%
KVS0001 is a selective SMG1 inhibitor. KVS0001 elevates the expression of transcripts and proteins resulting from truncating mutations. KVS0001 increased the presentation of immune-targetable HLA class I-associated peptides from nonsense-mediated decay (NMD)-downregulated proteins on the surface of cancer cells. KVS0001 exerts anti-tumor properties and can be studied in research for NMD-related diseases, including cancer and inherited diseases.

HY-132868

SLK/STK10-IN-1	Inhibitor	99.78%
SLK/STK10-IN-1 is a potent and selective inhibitor of SLK and STK10 with antitumor activity.

HY-103020

BAY-1816032	Inhibitor	99.73%
BAY-1816032, a chemical probe, is a potent and oral available BUB1 (budding uninhibited by benzimidazoles 1) kinase inhibitor with an IC₅₀ of 7 nM.

HY-178974

STK10-IN-1	Inhibitor
SLK/STK10-IN-2 (Compound 23) is a highly selective STK10 inhibitor, with a K_d of 365 nM and an IC₅₀ of 0.85 μM. SLK/STK10-IN-2 exhibits EC₅₀ of 0.89 μM in NanoBRET cell experiments. SLK/STK10-IN-2 shows no significant binding to SLK, STK3/4. SLK/STK10-IN-2 can be used to study STK10-related diseases (such as abnormal lymphocyte migration).

HY-147165

VT02956	Inhibitor	99.58%
VT02956 is a LATS inhibitor (IC₅₀: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids. VT02956 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-108333

SB-633825	Inhibitor	98.05%
SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC₅₀s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis.

HY-115677

ILK-IN-3	Inhibitor	99.62%
ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model.

HY-104001

BAY-524	Inhibitor	98.36%
BAY-524 is a potent Bub1 kinase inhibitor. BAY-524 inhibits the recombinant catalytic domain of human Bub1 with an IC₅₀ of 450 nM. BAY-524 can be used for the research of anti-cancer in combination with other agents.

HY-115719

NR162	Inhibitor	99.7%
NR162 is a selective CASK (Ca²⁺/calmodulin-dependent Ser/Thr kinase) inhibitor with an IC₅₀ of 80 nM and a Kd of 22 nM. NR162 shows about 50-fold selectivity for CASK than TYRO3. NR162 targets the unique GFG motif of CASK and has excellent shape complementarity to the CASK ATP binding pocket. NR162 can be used for the research of neurological diseases.

HY-W013852

PKC-IN-6	Inhibitor	99.93%
PKC-IN-6 (Compound 21) is a selective inhibitor of tyrosine and serine kinases. PKC-IN-6 shows inhibitory activity against PKC-α, PKC-δ, PKA, EGF-R with IC₅₀ values of 240, >500, >500, >100 μM, respectively. PKC-IN-6 is promising for research of cancers.

HY-145725A

Baliforsen	Inhibitor	98.12%
Baliforsen (ISIS 5987690) is an antisense oligonucleotide (ASO) that inhibits DMPK mRNA. Baliforsen binds within exon 9 of the human DMPK transcript to promote RNase H1-mediated degradation Baliforsen can be used for the research of myotonic dystrophy type 1.

HY-12240

B32B3	Inhibitor
B32B3 is an inhibitor of VprBP with an IC₅₀ value of 0.5 μM at the H2AT120p cell. B32B3 can suppress tumor growth.

HY-172241

Tapencarium	Inhibitor	99.53%
Tapencarium (RZL-012) is a serine/threonine kinase inhibitor. Tapencarium can reduce subcutaneous fat volume. Tapencarium is promising for research of fat-related disorders such as Dercum’s disease and aesthetic applications.

HY-180355

SY-5102	Inhibitor
SY-5102 is a potent, selective and orally active cyclin-dependent kinase (CDK7) inhibitor with a K_d of 0.03 nM. SY-5102 shows anti-proliferative activity against HCC70 cells with an EC₅₀ of 9 nM. SY-5102 can inhibit CDK7-mediated CAK function (downregulate CDK2 Thr160 phosphorylation) and TFIIH transcription function (downregulate RNA polymerase II Ser5 phosphorylation). SY-5102 can induce G2/M cell cycle arrest, downregulate the expression of the oncogene c-Myc, and ultimately trigger cancer cell apoptosis. SY-5102 can be used for the research of triple-negative breast cancer (TNBC).

HY-10424A

Milciclib maleate	Inhibitor
Milciclib (PHA-848125) maleate is a cyclin-dependent kinase inhibitor that impairs melanoma cell growth and modulates gene expression involved in cell cycle regulation. Milciclib maleate has been shown to significantly affect the expression of various genes, including down-regulating PTTG1, contributing to its antiproliferative activity. Milciclib maleate enhances sensitivity to treatment in p53 mutated melanoma cells when combined with PTTG1 silencing.

HY-177912

ILK-IN-4	Inhibitor
ILK-IN-4 (compound 49) is an integrin-linked kinase (ILK) inhibitor. ILK-IN-4 can be used for cancer research.

HY-128491

UNC10112785	Inhibitor
UNC10112785 is a serine/threonine kinase inhibitor with a human GSK-3β IC₅₀ of 0.031 μM, human CDK-2 IC₅₀ of 0.016 μM, and human CDK-4 IC₅₀ of 1.99 μM. UNC10112785 can be used for the research of type 2 diabetes.

HY-171294

Protein kinase inhibitor 16	Inhibitor
Protein kinase inhibitor 16 exhibits inhibitory activity against a variety of Ser/Thr kinase or receptor or non-receptor tyrosine kinase.

HY-116611

IMB-YH-8	Inhibitor
IMB-YH-8 is a serine/threonine protein kinase (PknB) inhibitor. IMB-YH-8 has strong antibacterial activity against Mycobacterium tuberculosis (MIC = 0.25 µg/mL). IMB-YH-8 can be used in the research of tuberculosis.

Name
Email *

	Sorry, but the email address you supplied was invalid.